Drugs / LY2608204

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT04907006 Aug → Oct 2021 type 2 diabetes mellitus Suzhou Yabao Pharmaceutical R&D Co., Ltd. Completed No outcome recorded
Phase 1 NCT04907019 Jul → Aug 2021 type 2 diabetes mellitus Suzhou Yabao Pharmaceutical R&D Co., Ltd. Completed No outcome recorded
Phase 1 NCT03414892 Jan 2018 → Jan 2019 hyperglycemia, type 2 diabetes mellitus Yabao Pharmaceutical Group Completed No outcome recorded
Phase 1 NCT03171623 Apr → Sep 2017 hyperglycemia Yabao Pharmaceutical Group Completed No outcome recorded
Phase 1 NCT01313286 Mar → Apr 2011 Eli Lilly and Company Completed No outcome recorded
Phase 1 NCT01247363 Nov 2010 → Mar 2011 type 2 diabetes mellitus Eli Lilly and Company Completed No outcome recorded
Phase 22 trials
Phase 2 NCT04217291 Dec 2019 → Jul 2021 type 2 diabetes mellitus Suzhou Yabao Pharmaceutical R&D Co., Ltd. Completed No outcome recorded
Phase 2 NCT01408095 Sep 2011 → Sep 2012 type 2 diabetes mellitus Eli Lilly and Company Withdrawn No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as LY2608204 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01247363
2

NCT01313286

NCT01408095

Known as Globalagliatin ClinicalTrials.gov intervention name — accepted as the source's own label NCT03414892
1

NCT03171623

Known as Globalagliatin Hydrochloride Globalagliatin Hydrochloride (SY-004)” NCT03414892
Known as LY-2608204 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297399
Known as SY-004 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04907019
2

NCT04217291

NCT04907006

Known as SY-004 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297399
Action Activate “Hexokinase type IV activator” CHEMBL4297399
1

“Glucokinase Activator” NCT01247363

Modality Small molecule CHEMBL4297399
Route Oral “Administered orally.” NCT01247363
Target GCK “Hexokinase type IV activator” CHEMBL4297399